Successful Treatment Options Expand to Earlier Lines in RCC and Urothelial Cancer
June 23rd 2022Tian Zhang, MD, discusses the benefits of multidisciplinary collaboration, how to select the best agents for each patient, and how treatments such as radiation in RCC and bladder-sparing chemoradiation in urothelial cancer fit into the overall treatment paradigms for these diseases.
ARO-HIF2 Lowers HIF2α Expression and Demonstrates Favorable Safety Profile in Clear Cell RCC
The investigational RNA interference therapy, ARO-HIF2, reduced levels of hypoxia inducible factor-2 alpha expression and had acceptable tolerability when used in patients with clear cell renal cell carcinoma, according to data from the phase 1b AROHIF21001 trial.
Tucatinib Plus T-DM1 Represents Another Potential Therapy in High-Risk HER2-Positive Breast Cancer
Heather McArthur, MD, MPH, discusses key treatment developments in early-stage and metastatic HER2-positive breast cancer and triple-negative breast cancer, plus ongoing research at UT Southwestern Harold C. Simmons Comprehensive Cancer Center.
Experimental Drug Could Spur Immunotherapy Response in Patients With Non–Small Cell Lung Cancer
April 5th 2022Research led by UT Southwestern scientists suggests that an investigational drug could restore the ability of some non–small cell lung cancers to respond to an immune checkpoint blockade, a therapy that harnesses the immune system to fight malignant tumors.
Pacritinib Paves a “Unique Lane” of Treatment for Select Myelofibrosis
April 5th 2022Patients who develop post–essential thrombocythemia myelofibrosis or post–polycythemia vera myelofibrosis, which are associated with significant symptom burden and bone marrow failure, have limited therapies available for effective treatment.
Capitalizing on Cellular Therapies in Lymphoma and Myeloma
January 18th 2021In our exclusive interview, Dr. Kansagra, Dr. D’Souza, and Dr. Dholaria provided an in-depth look into the current state of cellular therapy in hematologic malignancies, the benefits and drawbacks of approved and investigational products, and new constructs for CAR T in multiple myeloma and lymphoma.